*** Meet us at World ADC Summit 2019 – London – 5-6th March***
  • LinkedIn
  • English English English en
McSAF
  • About us
  • Team
  • Science
  • McSAF Inside® Oncology
  • Contact
  • Search
  • Menu Menu

Science

  • Home /
  • Science /

We believe personnalized medicine and targeted therapies are amazing therapeutic alternatives for many patients.

Our work focus on bringing chemical innovation to antibody-drug conjugates, a sub-class of targeted therapies, in order to ensure optimal characteristics and efficacies.

To date, McSAF have developped McSAF Inside® cysteins rebridging technology platforms that can be used to produce three typologies of ADCs:

  • DAR 4, i.e. 4 drugs per antibody
  • DAR 2, i.e. 2 drugs per antibody
  • DAR 1, i.e. 1 drug per antibody
  • Homogeneity

  • Site-specificity

  • Native proteins

  • Reproducibility

McSAF Inside®, a versatile technology

McSAF Inside® results

DAR 4

Results obtained on ADC with MMAE conventional linker (native mass spectrometry analysis)

DAR 2

Results obtained on ADC with MMAE click linker (native mass spectrometry analysis)

DAR 1

Results obtained on ADC with MMAE click linker (mass spectrometry analysis)

PATENTS & PUBLICATIONS

> Novel antibody-drug conjugates and the use of same in therapy Joubert, N ; Viaud-Massuard, MC ; Respaud, R. Patent WO2015004400A1. Patent granted in FR / US / JP / EP / CN / CA

> Antibody-drug conjugates and their use in therapy
Juen, L ; Baltus, CB.
Patent WO2020234541.

> Anti-CD30-drug conjugates and their use in therapy
Juen, L ; Baltus, CB.
Patent WO2021064332.

Patent granted in FR

> Anti-CD56 antibody-drug conjugates and their use in therapy
Juen, L ; Baltus, CB : Desgranges A ; Touzé, A ; Kervarrec, T ; Leblond, V ; Samimi, M.
Patent WO2021170961.

> Impact of Maleimide Disubstitution on Chemical and Biological Characteristics of HER2 Antibody-Drug Conjugates
Feuillâtre O. et al., ACS Omega, 2020, 5, 1557-1565

>Innovative Bioconjugation Technology for Antibody–Drug Conjugates: Proof of Concept in a CD30-Positive Lymphoma Mouse Model
Juen L. et al., Bioconjugate Chemistry, 2021, 32, 3, 595-606

>Adcitmer®, a new CD56-targeting monomethyl auristatin E-conjugated antibody, is a potential therapeutic approach in Merkel cell carcinoma
Esnault C. et al., British Journal of Dermatology, 2021

Scroll to top